After two years of treatment with bimekizumab, 53.1% of patients experienced mild disease compared to none at baseline.

Belgium’s largest drugmaker UCB today released long-term data from the BE HEARD^ trials for Bimzelx (bimekizumab) in moderate ...

Fact checked by Nick Blackmer It all started back in the spring of 2018 with a painful bump in my armpit. Confused, scared, ...

UCB, a global biopharmaceutical company, today announced long-term data from the BE HEARD^ trials for BIMZELX®▼ (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, ...

智通财经APP讯，华海药业(600521.SH)发布公告，近日，公司的下属子公司上海华奥泰生物药业股份有限公司(以下简称“华奥泰”)及华博生物医药技术(上海)有限公司(以下简称“华博生物”，华奥泰下属全资子公司)收到国家药品监督管理局核准签发的HB0 ...

The following is a summary of “Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: Results from a ...

The following is a summary of “Patients with PSOriasis and Suppurative Hidradenitis (PSO-SH) share genetic risk factors and are at risk of increased morbidity.,” published in the February 2025 issue ...

The use of combined oral contraceptives may delay the onset of hidradenitis suppurativa among women and may improve disease severity.

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

France: In a recent pilot study, researchers are investigating the efficacy of phenolization as a treatment for sinus tracts ...

Posting $162 million in fourth-quarter net sales, a 48% increase, and $508 million for the whole yeara 50% riseOpzelura ...